The purpose of the study is to find out which medicine better prevents low blood pressure (hypotension) while the patient is being treated before hospital admission. Participants who need pre‑hospital sedation and ventilation are randomly given either the test drug or the comparator drug. Their blood pressure and oxygen levels are monitored from the first reading in the ambulance until they leave the trauma centre, and their recovery is checked again about six months later.

During the observation period the study records any episodes of very low or very high blood pressure, as well as low oxygen levels, and later evaluates how well patients can perform everyday activities using standard rating scales that measure functional ability. No additional procedures beyond the emergency care needed for the injury are performed as part of the study.

The purpose of the study is to describe how well proportional sedation with transmucosal midazolam works and how well it is tolerated in pediatric palliative patients who have refractory symptoms.

Participants will receive the medication as prescribed, with regular observations to see how the symptoms respond and to monitor safety. The study follows each child for a period of time, collecting information on symptom relief and any side effects, before concluding the observation phase.

The purpose of the study is to determine whether a single course of the medication can help patients achieve a complete renal response, meaning the kidneys return to normal function according to international guidelines, one year after the first dose. Participants will receive the infusion at the start of the trial and will be monitored regularly with clinic visits, blood and urine tests, and questionnaires about daily living. Throughout the 52‑week follow‑up, researchers will record any side effects, track the need for additional medicines such as corticosteroids, and assess overall quality of life.

When a participant comes to the emergency department with a crisis, they receive either the inhaled medication or an oral opioid pill. Their pain level is recorded every ten minutes for the first hour using a line‑marking tool called the Visual Analog Scale. After one hour, the patient rates their overall satisfaction on a numbered rating system known as the Likert scale, and the attending nurse also records a satisfaction rating. Throughout the stay, the amount of any additional pain medicines given, the length of the hospital visit, and basic safety checks are noted, after which the patient is discharged.

Participants in the study will be divided into two groups. One group will receive meropenem through an intravenous infusion, which is a method of delivering medication directly into a vein. The other group will receive a placebo consisting of sodium chloride, a common salt solution. This process is conducted as a double-blind trial, meaning neither the patients nor the medical staff know which substance is being administered during the treatment period.

During the course of the study, medical professionals will monitor how the body responds to the treatment. The focus will be on observing survival rates and checking for organ dysfunction, which refers to a situation where vital organs such as the kidneys, liver, or lungs are not working correctly. The study will also track how long patients remain in the hospital and the overall progress of the illness following the administration of the medication.

Participants in this research will be assigned to receive either Vi-Siblin granules or a placebo. This is done through a process where neither the participants nor the researchers know which substance is being given. The study involves taking the granules by mouth over a period of time to see how they affect the severity of the symptoms and the overall quality of life.

The purpose of the study is to see if this step‑by‑step approach can improve outcomes for people with this high‑risk lymphoma. Participants will receive the initial combination of glofitamab plus chemotherapy in several treatment cycles, then undergo infusion of a CAR‑T product such as Breyanzi or Yescarta, and finally receive further glofitamab doses as consolidation. The whole sequence takes place over several months, with regular clinic visits for infusions, monitoring, and safety checks.

Throughout the trial, doctors will watch for any side effects, assess how well the disease responds, and evaluate overall health and quality of life. Follow‑up continues after the last treatment to see how long the response lasts and to track any late‑appearing effects.

For those with a high amount of the protein, AZD5335 will be compared to mirvetuximab soravtansine. For those with a low amount of the protein, AZD5335 will be compared to a treatment chosen by the doctor, which may include doxorubicin hydrochloride, liposomal, topotecan, or paclitaxel. These treatments are delivered through an intravenous infusion, which means the medicine is passed directly into a vein.

During the study, participants will receive their assigned treatment and will be monitored to see how long the cancer remains stable without growing. This period is referred to as progression-free survival. The study also looks at overall survival, which is the total length of time from the start of the study until death from any cause.

The purpose of the study is to evaluate the safety and effectiveness of a drug called R2R01. This medication is a Relaxin Agonist, which is a type of substance designed to activate specific proteins in the body to achieve a therapeutic effect. During the study, participants will receive either R2R01 or a placebo containing Sodium Chloride via a subcutaneous injection, which is an injection given into the fatty tissue just under the skin.

Participants will be assigned to different groups to receive different doses of the medication or the placebo. The study is double-blind, meaning that neither the participants nor the medical staff know which substance is being administered. The course of the study involves monitoring the participants after their surgery to observe how their kidneys function and to track any side effects that may occur.

Participants will undergo a period of treatment lasting six weeks. During this time, the effects of the pressurized oxygen on the wound’s environment and the healing process will be observed. The study will look at how the different types of microorganisms in the wound change and how this influences the body’s ability to repair the tissue and reduce the size of the sore.

The first group will receive etoposide very early, within 12 hours of being admitted to the study. The second group will follow a delayed strategy, where the medication is only started if the patient’s condition does not improve after 48 hours. During the course of the study, researchers will monitor how these different timing strategies affect the development or worsening of organ problems. The study will also look at various aspects of recovery, such as the length of time spent in the hospital and the need for support from machines like a ventilator, which helps a person breathe.

The purpose of the study is to assess how effective ATRA and tailored radiotherapy are in treating patients with localized squamous cell carcinoma of the head and neck. Participants in the study will receive either standard or reduced-target volume radiotherapy, with or without ATRA. The study will also involve the use of other medications, including cetuximab and cisplatin, which are commonly used in cancer treatment. Cetuximab is a protein-based medication, while cisplatin is a chemical compound used to stop the growth of cancer cells.

Throughout the study, participants will receive treatments over a period of time and will be monitored for their response to the therapy. The study aims to understand the impact of these treatments on the survival and quality of life of patients, as well as any potential side effects. The ultimate goal is to improve treatment strategies for head and neck cancer, providing better outcomes for patients.

The purpose of the study is to compare how the body processes these medicines when they are given under the skin compared to when they are given through a vein. During the study, patients will receive either the medicine under the skin or through a vein. Blood samples will be collected to measure the amount of medicine in the blood over time. This helps researchers understand if the medicine reaches the same levels in the body with both methods of giving it. The treatment period will last for up to ten days, and doctors will check how well the infection is responding to the treatment.

The study will also look at whether the medicine levels in the blood stay high enough to fight the infection effectively. Doctors will measure if the signs and symptoms of infection improve or go away without needing additional antibiotics. They will also check if the bacteria causing the infection are eliminated. Any side effects or unwanted reactions that occur during treatment and up to one day after treatment ends will be recorded. This information will help determine if giving these antibiotics under the skin is a safe and effective alternative to giving them through a vein.

The purpose of this study is to examine how memory-related brain networks are preserved or damaged in different groups of patients with memory disorders from various causes, and to understand the different types of memory strategies that memory experts use. The study will also include healthy people, professional theater actors, and memory athletes who compete in memory competitions. By comparing these different groups, researchers want to learn more about how the brain supports memory and what happens when memory becomes impaired.

Participants will undergo several days of testing and examinations. These will include brain scans using different techniques, memory and thinking tests, questionnaires about daily life and sleep, sleep monitoring, blood tests, and physical measurements. Some participants will receive the imaging substances to allow detailed pictures of their brain to be taken. The study will measure the size of different brain areas, how blood flows through the brain, and the presence of certain proteins that are associated with memory disorders. The information gathered will help researchers understand the brain structures and networks that support memory function in both healthy individuals and those with various memory problems.

During the study, patients with severe sudden pain will receive either morphine or alfentanil as their pain treatment. The medical team will measure the pain level using a number scale where patients rate their pain from zero to ten. The main focus is to see how many patients have their pain reduced to a low level within fifteen minutes after receiving the first injection of the assigned medicine. The study will also look at whether patients need additional pain medicine during their emergency care and how long it takes from the first injection until they arrive at the hospital.

The study will also carefully track any unwanted effects that might occur with either medicine. This includes checking breathing rate and oxygen levels, blood pressure, alertness and drowsiness, and whether patients experience nausea, vomiting, or itching. The medical team will monitor all these aspects throughout the emergency care period. The study will also examine whether the type of pain, such as pain from an injury or pain from internal organs, affects how well each medicine works.

The purpose of this study is to find out whether tislelizumab given as an injection under the skin reaches the same levels in the body as when it is given through a vein, and to see if the injection under the skin is as safe and effective as the intravenous method. The study will measure the amount of medication in the blood at different times and compare the results between the two groups. Researchers will also look at how well the treatment works by checking whether tumors shrink or stop growing, how long patients live without their cancer getting worse, and how long the treatment keeps working.

During the study, patients will receive tislelizumab in one of the two ways mentioned, along with chemotherapy, as their first treatment for this type of advanced cancer. The treatment can continue for up to 24 months. Throughout the study, doctors will monitor patients for any side effects and collect information about how the cancer responds to treatment. Patients will need to provide tumor tissue samples for testing, and the study will also check whether the body develops any immune responses against the medication.

During the study, participants will receive treatment for up to 104 weeks. The maximum daily dose of ALXN2030 that may be given is 450 milligrams. The study will examine whether the medication can help resolve the signs of rejection seen in kidney tissue samples, improve kidney function as measured by a blood test called estimated glomerular filtration rate, and reduce the activity of the rejection process. Before starting the study medication, all participants must be vaccinated against certain bacterial infections including meningococcal infection, pneumococcal infection, and Haemophilus influenzae type B infection, as the study medication may affect the immune system.

Throughout the study, doctors will monitor participants for any side effects or unwanted reactions to the treatment. They will also measure the amount of ALXN2030 in the blood over time and check if the body develops any antibodies against the study medication. The study will also track changes in certain proteins and immune system activity in the blood to understand how the medication works in the body. Kidney tissue samples will be taken at specific times during the study to assess whether the rejection process has improved or resolved.

The study aims to determine if methadone, when combined with current pain medication, is more effective at reducing bone pain than morphine in cancer patients. During the study, participants will receive either methadone or morphine capsules in addition to their regular pain medication. The treatment period lasts for three weeks, during which patients will need to take the study medication orally.

Throughout the study period, patients will record their pain levels and any side effects they experience. The study will also look at how the medications affect daily activities and overall quality of life. Both medications will be given in capsule form, with carefully controlled dosing to ensure patient safety.

During the study, participants who are hospitalized for rheumatological conditions will receive both forms of the medication at different times. The study will measure how the medication moves through the body and how well it is absorbed when given as a tablet compared to when it is given as an injection. This information will help determine the most effective way to give the medication to future patients.

The research will analyze several aspects of how the medication works in the body, including how long it takes to reach its highest level in the blood, how long it stays in the body, and how much of the medication becomes available for use. This information will help doctors better understand the differences between the tablet and injectable forms of Nefopam and potentially improve pain treatment for patients with rheumatological conditions.

The purpose of this research is to evaluate how atacicept affects certain proteins in patients with IgA Nephropathy. The medication comes in the form of a pre-filled syringe containing a solution for injection. During the study, participants will receive monthly injections of the study medication for 24 weeks.

Throughout the study period, various measurements will be taken to monitor protein levels in the blood and urine, as well as to check how well the medication is working and ensure patient safety. The total duration of treatment may last up to 48 weeks, during which patients will continue to receive their usual standard of care treatments for their condition.

The purpose of this study is to evaluate how safe atacicept is and how well it works in reducing the amount of protein in the urine. The medication is given as a subcutaneous injection using a pre-filled syringe. Participants will receive treatment while continuing their regular standard of care medications as prescribed by their doctors.

The study will last for 52 weeks, during which participants will receive regular doses of atacicept. Throughout the study, doctors will monitor various aspects of kidney function, particularly the amount of protein in the urine and how well the kidneys are filtering blood. They will also track the levels of specific disease markers in the blood that are associated with each type of kidney disease.

The purpose of this study is to evaluate how safe and well-tolerated these medications are when given in sequence, and to measure how they activate the immune system. Pseudovax will be given as an injection under the skin, while Tislelizumab will be administered through an intravenous infusion (directly into a vein). Molgramostim will also be given as an injection under the skin.

The treatment period will last several months, during which participants will receive regular doses of these medications. Throughout the study, doctors will monitor the participants’ health and measure how their immune system responds to the treatment. They will also track how long participants remain free from disease progression.

The purpose of this study is to investigate changes in the brain’s serotonin system during the early stages of Parkinson’s disease. The research specifically looks at people who carry a particular genetic change in the SNCA gene, which is associated with Parkinson’s disease. The study will compare these individuals with healthy people who do not have this genetic change.

During the study, participants will receive the imaging substances through an intravenous injection. They will undergo brain scanning procedures that include MRI (Magnetic Resonance Imaging) and other specialized imaging tests. The study will examine how these substances bind to specific areas in the brain and what this reveals about the early stages of the disease.

The main purpose is to understand how these medications can help protect kidney function and improve blood vessel health in people with CKD. During the study, participants will receive different doses of the medications: semaglutide injections ranging from 0.25 mg to 1 mg, and finerenone tablets in either 10 mg or 20 mg strengths.

The study will measure how well the medications work by looking at changes in the amount of protein in participants’ urine, which is an important indicator of kidney health. The treatment will involve two separate periods: first, participants will receive either semaglutide or no treatment, and then in the second period, all participants will receive finerenone in addition to their existing treatment.

The research evaluates how well the kidneys filter blood (called glomerular filtration) and how this affects morphine processing in the body. By measuring kidney function using iohexol clearance (a reference method) and comparing it to a kidney function estimation tool (CKD-Epi score), researchers hope to determine when standard morphine doses might not provide adequate pain relief for certain patients.

Understanding the relationship between kidney function and morphine effectiveness could help doctors identify which patients need higher initial doses of pain medication. This would allow for more personalized pain management strategies for people with sickle cell disease during painful crises, potentially improving treatment outcomes and patient comfort.

The purpose of the study is to determine if taking 40 mg of Pravastatin daily can help prolong pregnancy in women diagnosed with severe early-onset preeclampsia or IUGR between 24 and 29 weeks of gestation. Participants in the study will be randomly assigned to receive either Pravastatin or a placebo, which looks like the medication but does not contain the active ingredient. The study will monitor the duration of pregnancy from the time of inclusion until delivery.

Participants will take the medication orally in the form of a tablet. The study aims to provide insights into whether Pravastatin can be an effective treatment strategy for managing these conditions and potentially improving outcomes for both mothers and their babies. The trial is expected to continue until the end of 2027, with recruitment starting in 2025.

Participants in the study will receive one of the two treatment combinations. The first group will take tacrolimus and MTOR inhibitors, while the second group will take tacrolimus and mycophenolic acid. Both groups will be monitored for their immune response to CMV before the transplant and at 15, 30, and 90 days after the transplant. The study will also track the presence of CMV infection or disease six months after the transplant to evaluate the effectiveness of each treatment approach.

The study will last until the end of 2026, with recruitment starting in mid-2025. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatments. The findings from this study could help improve the management of CMV infection in kidney transplant recipients, potentially leading to better outcomes for patients with advanced chronic kidney disease.

The purpose of the study is to assess how these interventions can help reduce inflammation and improve overall health outcomes in high-risk individuals. The study will involve regular monitoring and assessments over a period of time to observe changes in health markers, such as inflammation levels and smoking habits. Participants will be randomly assigned to different groups, with some receiving the active medications and others receiving a placebo.

Throughout the study, participants will be encouraged to follow a healthy lifestyle, including adherence to the Mediterranean Diet and increased physical activity. The study will also track various health indicators, such as weight, waist circumference, and blood markers, to evaluate the overall impact of the interventions. The ultimate goal is to determine if these treatments can lead to a reduction in the incidence of lung cancer and improve the quality of life for those at high risk.

The purpose of the study is to compare the porosity, or how easily fluid passes through, of the superficial lymphatic vessels in women with lipedema versus those in healthy individuals. This will help determine if the imaging technique, known as Near Infra-Red Fluorescence Imaging (NIRFI), can be a useful tool for diagnosing lipedema. The study involves injecting the indocyanine green just under the skin and then using the imaging technique to observe how the lymphatic vessels behave.

Participants in the study will undergo this imaging process, and researchers will observe the fluorescence in the area around the lymphatic vessels. They will also measure how quickly the contrast moves through the vessels and the pressure needed to block the flow in these vessels. The study is designed to provide insights into the differences in lymphatic vessel function between those with lipedema and those without, potentially leading to better diagnostic methods for this condition.

The purpose of the study is to explore the relationship between brain inflammation and genetic factors in people with schizophrenia. The study will include both patients with schizophrenia and healthy volunteers. Participants will undergo PET scans to measure brain inflammation and may also have other types of scans, like MRI, to look at brain structure and connections. The study will also check for other health markers, such as cholesterol levels and blood sugar, to see how they relate to brain inflammation.

The study will take place over several years, with the goal of better understanding how genetic factors might influence brain inflammation in schizophrenia. This research could help in developing new ways to diagnose or treat the condition in the future.

The study is divided into two parts. In the first part, researchers aim to develop a tool that helps determine the right dose of Sevuparin for each individual based on their kidney function. This is done by looking at how the body processes the medication. In the second part, the study will look at changes in important blood and kidney health markers after multiple doses of Sevuparin are given to participants with CKD. These markers include things like blood cell levels and kidney function indicators.

Throughout the study, participants will be closely monitored for safety, with regular checks on their heart activity, vital signs, and blood tests. The study will also assess any side effects that may occur. The goal is to gather information that could lead to better treatment options for people living with Chronic Kidney Disease.

The study is divided into two parts. In the first part, healthy volunteers will receive the NEP-1 injection to determine the right dose and timing for examining lymph nodes using the NanoEcho Imaging Device. In the second part, patients with rectal cancer will receive the same treatment to confirm the findings from the first part. The study aims to see how well the device can detect changes in the lymph nodes and to ensure the treatment is safe for patients.

Participants in the study will receive the NEP-1 injection and undergo imaging with the NanoEcho Imaging Device. The study will monitor the size and distance of lymph nodes from the injection site and check for any side effects or changes in health. The goal is to improve the understanding of how rectal cancer spreads and to develop better ways to detect it early. The study is expected to continue until mid-2025.

The treatment being tested involves two main substances. The first is lidocaine hydrochloride, a local anesthetic that helps numb the area to reduce pain. The second is sodium chloride, commonly known as salt, which is used as a solvent to help deliver the lidocaine. Both substances are administered through a subcutaneous injection, which means they are injected just under the skin.

The purpose of the study is to determine how effective this nerve block treatment is in managing headache pain related to spontaneous subarachnoid hemorrhage. Participants in the study will receive the treatment and their headache pain will be monitored to see if there is a significant reduction in pain levels. The study will help understand if this approach can provide relief for those suffering from this type of headache.

The purpose of the study is to see how well IV NEPA works in preventing nausea and vomiting in children receiving chemotherapy. The study will be conducted in two parts. In the first part, children will receive a single dose of IV NEPA and will be compared to those receiving fosaprepitant and ondansetron. In the second part, children will receive repeated doses of IV NEPA and will be compared to those receiving a combination of aprepitant and ondansetron. The study will monitor the safety and effectiveness of these treatments over time.

Participants in the study will receive their assigned treatment and will be closely monitored by healthcare professionals. The study aims to provide valuable information on the best ways to prevent nausea and vomiting in children undergoing chemotherapy, helping to improve their comfort and quality of life during treatment. The study is expected to continue until the end of 2027.

The purpose of the study is to compare the effectiveness and safety of two different treatment plans using Rituximab for maintaining remission in adults with relapsing nephrotic syndrome. Participants in the study will be randomly assigned to one of the two treatment plans. The study will observe how long it takes for the nephrotic syndrome to return after starting the treatment. The trial will also look at other factors, such as the number of relapses over a period of 24 months, the amount of steroid medication needed, and any side effects experienced by participants.

Throughout the study, participants will receive regular check-ups to monitor their health and the progress of their condition. The study aims to provide valuable information on how to best manage relapsing nephrotic syndrome with Rituximab, potentially improving treatment outcomes for those affected by this condition. The trial is expected to continue for several years to gather comprehensive data on the long-term effects and benefits of the treatment.

The treatment being tested involves the use of medications containing amoxicillin and clavulanic acid. These are antibiotics that help fight infections by killing bacteria or preventing their growth. In this study, these medications are given in two forms: a solution for injection or infusion, and film-coated tablets. The trial will compare this new approach to the standard treatment to see if it is just as effective in preventing complications after surgery, such as infections or other issues that might require further medical attention.

Participants in the study will undergo a surgical procedure called a laparoscopic appendectomy, which is a minimally invasive surgery to remove the appendix. After the surgery, they will receive the study treatment and be monitored for any adverse events, such as infections or complications, for 30 days. The goal is to determine if the Fast Track strategy can safely reduce the length of hospital stays without increasing the risk of complications. This study is important for improving recovery times and overall outcomes for children with complicated acute appendicitis.

The purpose of the study is to evaluate how effective Alpha-1 Antitrypsin is in reducing inflammation in patients with severe forms of this liver condition. Participants in the study will receive the treatment once a week for four weeks. Some participants will receive a placebo instead of the active treatment. The study will monitor the effects of the treatment over a period of time to see if it helps improve the condition of the liver and overall health of the participants.

Throughout the study, participants will have regular check-ups to assess their health and any changes in their condition. The study aims to gather information on the safety and effectiveness of Alpha-1 Antitrypsin as a potential treatment for Alcohol-Associated Hepatitis. This research could provide valuable insights into new ways to manage and treat this liver disease.

Participants in the study will receive either Midazolam or Morphine through injections, which can be given intravenously (into a vein), subcutaneously (under the skin), or intramuscularly (into a muscle). The study will monitor how quickly symptoms are relieved after the medication is administered and will also track any adverse reactions, such as nausea, vomiting, or hallucinations. The study aims to provide valuable information on the effectiveness and safety of these medications in managing end-of-life symptoms.

The trial will take place over a period of time, with each participant being observed for up to 14 days. The information gathered will help healthcare providers better understand the relationship between the dosage of these medications and their impact on symptom control and side effects. This study is an important step in improving the quality of care for elderly patients in their final days.

The purpose of the study is to evaluate whether taking a low dose of Carvedilol (up to 12.5 mg per day) can prevent the worsening of cirrhosis or liver-related death over a period of 36 months. Participants in the study will be randomly assigned to receive either the medication or a placebo, which looks like the medication but does not contain any active ingredients. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will be monitored for any changes in their condition, including the occurrence of cirrhosis complications or liver-related death. The safety of Carvedilol will also be assessed by observing its effects on heart rate, blood pressure, and overall cardiac function. Additionally, researchers will look for any potential predictors of how patients respond to the treatment, such as changes in liver and spleen stiffness or variations in heart rate and blood pressure. The study aims to provide valuable insights into the management of cirrhosis and improve outcomes for patients with this condition.